LAVA Therapeutics (NASDAQ:LVTX) Issues Earnings Results

LAVA Therapeutics (NASDAQ:LVTX) announced its quarterly earnings data on Tuesday. The company reported ($0.31) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.05, Yahoo Finance reports. LAVA Therapeutics had a negative return on equity of 51.90% and a negative net margin of 228.02%.

LAVA Therapeutics Stock Performance

LVTX stock traded up $0.07 during trading on Thursday, hitting $1.87. 61,295 shares of the company traded hands, compared to its average volume of 751,468. LAVA Therapeutics has a 1 year low of $1.13 and a 1 year high of $6.47. The company has a market cap of $47.40 million, a PE ratio of -1.73 and a beta of 0.54. The stock’s 50-day simple moving average is $1.92 and its 200 day simple moving average is $2.40. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.42 and a quick ratio of 7.42.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on LVTX shares. JMP Securities reiterated a “market outperform” rating and issued a $6.00 price target on shares of LAVA Therapeutics in a report on Wednesday. HC Wainwright reiterated a “buy” rating and issued a $6.00 price objective on shares of LAVA Therapeutics in a research note on Friday, June 28th.

LAVA Therapeutics Company Profile

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.